<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857544</url>
  </required_header>
  <id_info>
    <org_study_id>VGFT-OD-1313</org_study_id>
    <secondary_id>VGFT-OD-1313</secondary_id>
    <nct_id>NCT01857544</nct_id>
  </id_info>
  <brief_title>Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy</brief_title>
  <official_title>Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tennessee Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tennessee Retina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine the number of patients with complete resolution of&#xD;
      macular edema secondary to central retinal vein occlusion following 6 monthly injections of&#xD;
      Aflibercept.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty (20) consented participant who meet the inclusion criteria will be enrolled to be&#xD;
      followed for 6 months. All subjects will receive monthly 2.0 mg intravitreal aflibercept&#xD;
      injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>From baseline to Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of reduction in macular thickness</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of reduction in macular volume</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in best-corrected visual acuity (BCVA)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with gain or loss of 5, 10, and 15 letters in BCVA</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>6 month-period</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect on macular leakage using fluorescein angiogram (FA)</measure>
    <time_frame>Month 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect on peripheral retinal non-perfusion</measure>
    <time_frame>Month 6</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Aflibercept 2.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Monthly 2.0mg Aflibercept Intravitreal Injection</description>
    <arm_group_label>Aflibercept 2.0mg</arm_group_label>
    <other_name>VEGF-Trap</other_name>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:A patient must meet the following criteria to be eligible for inclusion&#xD;
        in the study:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Documented macular edema following central retinal vein occlusion&#xD;
&#xD;
          -  Currently receiving treatment with intravitreal anti-VEGF therapy initiated at least 3&#xD;
             months months previously&#xD;
&#xD;
          -  Documented intravitreal treatment with ranibizumab 0.5 mg (at least 3 doses, each one&#xD;
             month apart) or bevacizumab 1.25 mg (at least 3 doses, each one month apart)&#xD;
&#xD;
          -  Presence of persistent macular edema (defined as any of the following):&#xD;
&#xD;
               -  central foveal thickness (CFT) of &gt; 300 microns by spectral-domain OCT&#xD;
&#xD;
               -  presence of any intraretinal or subretinal fluid&#xD;
&#xD;
               -  Receipt of intravitreal anti-VEGF injections more frequently than once per month&#xD;
&#xD;
          -  Willingness and ability to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Ability to provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior vitrectomy in the study eye&#xD;
&#xD;
          -  Concurrent retinal vascular disease in the study eye that could compromise visual&#xD;
             acuity or contribute to macular edema (e.g. diabetic retinopathy, age-related macular&#xD;
             degeneration)&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy,&#xD;
             advanced glaucoma) that, in the opinion of the investigator, could either&#xD;
&#xD;
               -  require medical or surgical intervention during the 6-month study period to&#xD;
                  prevent or treat visual loss; or,&#xD;
&#xD;
               -  if allowed to progress untreated, contribute to loss of at least 2 Snellen&#xD;
                  equivalent lines of best corrected visual acuity over the 6 month study period&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye, or history of&#xD;
             idiopathic or autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye&#xD;
&#xD;
          -  Intraocular surgery (including cataract surgery) in the study eye within 60 days&#xD;
             preceding baseline&#xD;
&#xD;
          -  Systemic anti-VEGF treatment within the last 3 months prior to screening&#xD;
&#xD;
          -  Prior intravitreal aflibercept injection in the study eye&#xD;
&#xD;
          -  Macular laser photocoagulation within 4 months of screening&#xD;
&#xD;
          -  Intravitreal or periocular corticosteroid within 4 months of screening&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure â‰¥30 mmHg&#xD;
             despite treatment with ocular antihypertensive medication)&#xD;
&#xD;
          -  Allergy to fluorescein, povidone iodine (Betadine) or aflibercept&#xD;
&#xD;
          -  Participation in a study of an investigational drug or device within 30 days prior to&#xD;
             potential enrollment into the study&#xD;
&#xD;
          -  Patients with cognitive dysfunction such as dementia, Alzheimer's disease or any other&#xD;
             neuro-degenerative disorder.&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Sexually active men* or women of childbearing potential** who are unwilling to&#xD;
             practice adequate contraception during the study (adequate contraceptive measures&#xD;
             include stable use of oral contraceptives or other prescription pharmaceutical&#xD;
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device;&#xD;
             bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly,&#xD;
             or diaphragm plus contraceptive sponge, foam, or jelly)&#xD;
&#xD;
               -  Contraception is not required for men with documented vasectomy. **Postmenopausal&#xD;
                  women must be amenorrheic for at least 12 months in order not to be considered of&#xD;
                  child bearing potential. Pregnancy testing and contraception are not required for&#xD;
                  women with documented hysterectomy or tubal ligation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco M Recchia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennessee Retina, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tennessee Retina, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal Vein Occlusion</keyword>
  <keyword>Central Retinal Vein Occlusion</keyword>
  <keyword>Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

